TABLE. Number and percentage of countries that included eight World Health Organization–recommended new and underutilized vaccines* available in their national routine immunization schedule, by year — worldwide, 2016–2021.
| Year | No. (%),
yr WHO recommended† |
|||||||
|---|---|---|---|---|---|---|---|---|
| DTPCV4 2017§ | HepB-BD 2009 | Hib 2006 | HPV 2009¶ | MCV2 2009 | PCV 2007 | RCV 2000** | RV 2009 | |
| 2016 |
135 (70) |
100 (52) |
190 (98) |
69 (36) |
164 (85) |
132 (68) |
155 (80) |
84 (43) |
| 2017 |
136 (70) |
104 (54) |
190 (98) |
79 (41) |
167 (86) |
135 (70) |
160 (82) |
91 (47) |
| 2018 |
137 (71) |
106 (55) |
191 (98) |
87 (45) |
171 (88) |
138 (71) |
168 (87) |
95 (49) |
| 2019 |
138 (71) |
109 (56) |
192 (99) |
103 (53) |
177 (91) |
144 (74) |
173 (89) |
105 (54) |
| 2020 |
137 (71) |
110 (57) |
192 (99) |
107 (55) |
179 (92) |
146 (75) |
173 (89) |
111 (57) |
| 2021 | 140 (72) | 111 (57) | 192 (99) | 114 (59) | 183 (94) | 152 (78) | 173 (89) | 116 (60) |
Abbreviations: DTPCV4 = first booster dose of diphtheria, tetanus, and pertussis–containing vaccine; HepB-BD = universal hepatitis B vaccine birth dose; Hib = Haemophilus influenzae type b vaccine; HPV = human papillomavirus vaccine; MCV2 = second dose of measles-containing vaccine; PCV = pneumococcal conjugate vaccine; RCV = rubella-containing vaccine; RV = rotavirus vaccine; WHO = World Health Organization.
* Vaccine introduction data for DTPCV4 was unavailable for 2016. For all other vaccines, no value indicates no introductions occurred for that year.
† Year WHO recommended inclusion of vaccine in all national routine immunization programs.
§ In 2017, WHO revised its DTPCV booster recommendations, shifting the first booster dose of tetanus to the second year of life to align with the recommendation for the first booster dose of pertussis. Countries reporting inclusion of DTPCV4 in this table might provide it at any age.
¶ HPV was originally recommended as a 3-dose schedule for girls aged 9–13 years in 2009 and updated to a 2-dose schedule recommendation in 2014 for girls aged 9–14 years; an alternative single-dose schedule was recommended in 2022 for girls aged 9–14 years.
** In 2000, WHO recommended introduction of RCV in countries where it can be safely introduced.